Role of Immunotherapy in Pulmonary Angiosarcoma: A Case Report

Abstract

Pulmonary angiosarcoma is a rare clinical entity with a poor prognosis and no established therapeutic strategies. We present the first case to our knowledge of metastatic pulmonary angiosarcoma, treated with checkpoint inhibitor immunotherapy, and have an excellent response. Until now, patient has been treated with immunotherapy for 1 year, and his disease is stable and well-tolerated.

Keywords

• pulmonary angiosarcoma
• immunotherapy
• prembrolizumab